Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Epigenetic reprogramming and exosome blockade to enhance immune checkpoint therapy in ovarian cancer
FY 2025-26
Summary
Ovarian cancer is the deadliest type of cancer affecting the female reproductive system. While surgery and chemotherapy are commonly used to treat it, many patients experience a recurrence of the disease that no longer responds to treatment. Immunotherapy—a treatment that can help the body’s immune system fight cancer—has worked well in many cancer types, but not in ovarian cancer. One possible reason is that ovarian tumours create a surrounding environment that weakens the immune system’s ability to attack cancer cells. This unique environment is likely the result of multiple factors. One of these factors may be the role of the SWI/SNF complex. This protein complex makes our DNA more or less accessible to read, and is made up of multiple components. We have previously shown that blocking the BRG1 component of this complex can increase immune-simulating signals and activate immune cells surrounding ovarian cancer cells. In addition, tiny particles called exosomes, which cancer cells use to communicate with one another, can weaken the immune system’s recognition of cancer as well. We have recently shown that blocking the release of these exosomes can also increase immune-stimulating signals. By targeting these two mechanisms through this project, we aim to reverse this weakened tumor immune environment and make ovarian cancer more responsive to immunotherapy. This work is directly relevant to women’s cancer research and has the potential to improve outcomes for ovarian cancer patients, addressing a major health challenge for women worldwide. This project’s innovative approach could significantly enhance ovarian cancer treatment and pave the way for future immunotherapy combination strategies.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573132
Name
David Lisa M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Epigenetic reprogramming and exosome blockade to enhance immune checkpoint therapy in ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Brg1; Chromatin Remodelling; Epigenetic Therapy; Extracellular Vesicle Blockade; Immune Checkpoint Blockade; Immune Tumour Microenvironment; Ovarian Cancer
Abstract
Ovarian cancer is the deadliest type of cancer affecting the female reproductive system. While surgery and chemotherapy are commonly used to treat it, many patients experience a recurrence of the disease that no longer responds to treatment. Immunotherapy—a treatment that can help the body’s immune system fight cancer—has worked well in many cancer types, but not in ovarian cancer. One possible reason is that ovarian tumours create a surrounding environment that weakens the immune system’s ability to attack cancer cells. This unique environment is likely the result of multiple factors. One of these factors may be the role of the SWI/SNF complex. This protein complex makes our DNA more or less accessible to read, and is made up of multiple components. We have previously shown that blocking the BRG1 component of this complex can increase immune-simulating signals and activate immune cells surrounding ovarian cancer cells. In addition, tiny particles called exosomes, which cancer cells use to communicate with one another, can weaken the immune system’s recognition of cancer as well. We have recently shown that blocking the release of these exosomes can also increase immune-stimulating signals. By targeting these two mechanisms through this project, we aim to reverse this weakened tumor immune environment and make ovarian cancer more responsive to immunotherapy. This work is directly relevant to women’s cancer research and has the potential to improve outcomes for ovarian cancer patients, addressing a major health challenge for women worldwide. This project’s innovative approach could significantly enhance ovarian cancer treatment and pave the way for future immunotherapy combination strategies.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
David, Lisa M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~